Diflucan Shortage: What Providers and Prescribers Need to Know in 2026

Fluconazole (Diflucan) is one of the most frequently prescribed antifungal agents in outpatient and inpatient settings. As a cornerstone treatment for vaginal candidiasis, oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and antifungal prophylaxis in immunocompromised patients, ensuring consistent access for your patients is clinically meaningful. This briefing reviews availability status in 2026, clinical considerations, and tools to support patient access.

Current Shortage Status (2026)

As of 2026, oral fluconazole tablets and suspension are not listed on the FDA Drug Shortages Database or the ASHP Drug Shortage Bulletin as a current active shortage. Generic fluconazole is manufactured by multiple domestic and international producers, creating supply redundancy that has historically protected oral formulations from national-level shortages.

However, prescribers should be aware that individual patients may still report difficulty filling prescriptions due to:

Localized pharmacy-level stockouts, particularly for the 150 mg tablet (single-dose vaginal candidiasis treatment)

Oral suspension supply variability (more variable than tablets due to fewer manufacturers)

IV fluconazole, which has historically been more prone to hospital-level shortages as part of the broader sterile injectable drug shortage problem

FDA-Approved Indications: Clinical Reminder

Fluconazole is FDA-approved for the following indications:

Vaginal candidiasis (150 mg single dose)

Oropharyngeal candidiasis (200 mg loading dose, then 100 mg daily × 2 weeks)

Esophageal candidiasis (200 mg loading, then 100–200 mg daily × ≥3 weeks)

Candidemia and disseminated candidiasis (400–800 mg daily)

Cryptococcal meningitis (400 mg loading dose, then 200–400 mg daily for 10–12 weeks post-CSF culture negative)

Candidiasis prophylaxis in bone marrow transplant patients (400 mg daily)

Off-label uses supported by evidence include: weekly maintenance therapy for recurrent vulvovaginal candidiasis (RVVC), tinea versicolor, coccidioidomycosis (non-meningeal), and onychomycosis.

Prescribing Considerations: Renal and Hepatic Adjustment

Fluconazole is primarily renally cleared (~80% unchanged in urine). Dose adjustment is required in patients with creatinine clearance below 50 mL/min for multi-dose regimens (generally reduce dose by 50% or double the dosing interval). Single-dose therapy for vaginal candidiasis does not require renal adjustment. Fluconazole should be used with caution in patients with hepatic dysfunction; hepatotoxicity, though rare, is more likely in patients with serious underlying disease.

Key Drug Interactions to Review Before Prescribing

Fluconazole is a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4. Clinically significant interactions include:

Warfarin: Significantly increases prothrombin time. Monitor INR closely; dose adjustment of warfarin likely required.

Erythromycin, pimozide, quinidine: Contraindicated due to additive QT prolongation via CYP3A4 inhibition.

Clopidogrel: Reduced antiplatelet effect via CYP2C19 inhibition. Consider alternative antifungal or antiplatelet agent.

Tacrolimus, cyclosporine: Significantly increased immunosuppressant levels. Monitor trough levels closely if co-prescribing.

Sulfonylureas (glipizide, glyburide): Increased hypoglycemic effect via CYP2C9 inhibition. Monitor blood glucose.

Amiodarone: Additive QT prolongation risk. Use with caution; ECG monitoring recommended.

Antifungal Alternatives If Fluconazole Is Unavailable or Inappropriate

When fluconazole is unavailable or contraindicated, consider the following evidence-based alternatives by indication:

Vaginal candidiasis (uncomplicated): OTC topical miconazole (Monistat) or clotrimazole vaginal cream — clinically equivalent for most patients. Prescription clotrimazole troches or itraconazole for recalcitrant cases.

Oropharyngeal candidiasis: Clotrimazole troches 10 mg 5× daily × 14 days; nystatin suspension 4–6 mL swish-and-swallow 4× daily × 14 days. For fluconazole-refractory OPC: itraconazole oral solution 200 mg daily.

Esophageal candidiasis: Itraconazole oral solution 200 mg daily × 14–21 days (equivalent efficacy to fluconazole per IDSA guidelines). Echinocandins (micafungin, anidulafungin, caspofungin) for refractory cases.

Candidemia/invasive candidiasis: Echinocandin (caspofungin, micafungin, or anidulafungin) is the preferred initial therapy per IDSA 2016 guidelines for most non-neutropenic patients. Step-down to fluconazole once susceptibility confirmed and patient clinically stable.

Cryptococcal meningitis: For induction: liposomal amphotericin B + flucytosine × 2 weeks. Consolidation phase: fluconazole 400 mg daily × 8 weeks. If fluconazole unavailable for consolidation, consult infectious disease.

Supporting Patient Access: Tools for Prescribers

When patients call your office unable to fill a fluconazole prescription, these resources can help:

medfinder for Providers: medfinder.com/providers — Helps your patients locate pharmacies with medications in stock. Your patients can use medfinder to find where fluconazole is available near them without calling pharmacies themselves.

ASHP Drug Shortage Database: ashp.org — For monitoring official shortage status updates across all formulations.

FDA Drug Shortages page: accessdata.fda.gov — For regulatory updates and current shortage listings.

Bottom Line for Prescribers

Oral fluconazole tablets are generally well-supplied in 2026 with no active national shortage. Prescribers should anticipate occasional patient-level access difficulties — primarily for the 150 mg tablet — that can be resolved by directing patients to alternate pharmacies or medfinder. For serious fungal infections, have an alternative antifungal plan ready. See our companion guide: How to Help Your Patients Find Diflucan in Stock.